Liver Fibrosis Market Report

Liver Fibrosis companies are 89bio Inc., HighTide Biopharma, Rivus Pharmaceuticals Inc, Novo Nordisk A/S, and others.

LAS VEGAS, NEVADA, UNITED STATES, June 13, 2024 /EINPresswire.com/ -- DelveInsight’s “Liver Fibrosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Recent breakthroughs in the Liver Fibrosis Market:

On March 14, 2024, the U.S. Food and Drug Administration (FDA) approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) who have moderate to advanced liver scarring (fibrosis). Rezdiffra is used in conjunction with diet and exercise. This approval marks a significant step in addressing liver damage for patients with NASH and notable liver scarring.

To Know in detail about the Liver Fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Liver Fibrosis Market Forecast

Some of the key facts of the Liver Fibrosis Market Report:

The Liver Fibrosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
The Liver Fibrosis Market is expected to strengthen as awareness of the disease increases and more effective interventions are being developed.
Key Liver Fibrosis Companies: Inventiva Pharma, Galmed Research and Development, Ltd., Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, Galectin Therapeutics Inc., Zydus Therapeutics, Axcella Therapeutics, Akero Therapeutics, Inc, Lipocine Inc., Enyo Pharma, Sagimet Biosciences Inc., 89bio Inc., HighTide Biopharma, Rivus Pharmaceuticals Inc, Novo Nordisk A/S, and others
Key Liver Fibrosis Therapies: Lanifibranor, Aramchol, and others
The Liver Fibrosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Liver Fibrosis pipeline products will significantly revolutionize the Liver Fibrosis market dynamics.

Liver Fibrosis Overview

Liver fibrosis leads to the buildup of extracellular matrix (ECM) proteins, primarily collagens Type I and Type III, which then results in the development of fibrous scars. This scarring can eventually impair the normal functioning of the liver. The primary factors contributing to liver fibrosis include excessive alcohol consumption, chronic infection with hepatitis C virus (HCV), non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis (NASH), which is a form of fatty liver not caused by alcohol consumption. Irrespective of the underlying cause, liver fibrosis is defined by shared molecular processes such as the death of liver cells (hepatocytes), persistent inflammation accompanied by the release of cytokines, the activation of hepatic stellate cells (HSCs), and the breakdown of the epithelial or endothelial barrier.

Liver Fibrosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
According to an assessment by DelveInsight, the total number of diagnosed prevalent cases of liver fibrosis in the 7MM was estimated at 19,126,579 in 2021.
The United States reported the highest number of diagnosed prevalent cases of liver fibrosis in 2021, with 9,488,135 cases, and this figure is anticipated to increase in the future.
Within European countries, Germany had the highest count of diagnosed prevalent cases of liver fibrosis in 2021, with 1,641,162 cases, followed by Italy, which had a diagnosed population of 1,532,651. Conversely, Spain had the lowest number of diagnosed individuals, with 1,307,582 cases.
Japan accounted for 2,299,149 diagnosed cases of liver fibrosis in 2021, representing approximately 12% of the total in the 7MM.
Liver Fibrosis Epidemiology Segmentation:
The Liver Fibrosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Liver Fibrosis
Prevalent Cases of Liver Fibrosis by severity
Gender-specific Prevalence of Liver Fibrosis
Diagnosed Cases of Episodic and Chronic Liver Fibrosis

Download the report to understand which factors are driving Liver Fibrosis epidemiology trends @ Liver Fibrosis Epidemiology Forecast

Liver Fibrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Liver Fibrosis market or expected to get launched during the study period. The analysis covers Liver Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Liver Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Liver Fibrosis Emerging Drugs Profile

Lanifibranor: Inventiva Pharma
Aramchol: Galmed Research and Development

Liver Fibrosis Therapies

Inventiva Pharma, Galmed Research and Development, Ltd., Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, Galectin Therapeutics Inc., Zydus Therapeutics, Axcella Therapeutics, Akero Therapeutics, Inc, Lipocine Inc., Enyo Pharma, Sagimet Biosciences Inc., 89bio Inc., HighTide Biopharma, Rivus Pharmaceuticals Inc, Novo Nordisk A/S

Liver Fibrosis Therapies

Lanifibranor, Aramchol

Discover more about therapies set to grab major Liver Fibrosis market share @ Liver Fibrosis Treatment Landscape

Liver Fibrosis Market Outlook

Liver fibrosis results from the excessive accumulation of extracellular matrix (ECM) in response to chronic liver injury, functioning as a model for the wound healing process. This process involves an inflammatory response where ECM deposition is initially restricted. However, persistent liver damage disrupts liver regeneration, leading to the replacement of hepatocytes with large amounts of ECM, including collagen.

There is growing optimism that new medications favoring the natural progression of the disease may emerge within the next 3-5 years. Currently, due to the lack of standard treatments, liver transplantation remains the only option for severe and advanced fibrosis cases. No drug has been FDA-approved specifically for fibrosis or nonalcoholic steatohepatitis (NASH), although some studies have shown promising results. According to the American Liver Foundation guidelines, Vitamin E is commonly prescribed for patients with nonalcoholic fatty liver disease (NAFLD) or NASH to reduce or neutralize inflammation-related damage. Both Vitamin E, as an antioxidant, and pioglitazone, as an insulin sensitizer, have demonstrated some efficacy against NASH in randomized controlled trials (RCTs).

Looking ahead, numerous pharmaceutical companies are investigating agents for use in NASH-based fibrosis, including Inventiva Pharma, Galmed Pharmaceuticals, Madrigal Pharma, Galectin Therapeutics, Intercept Pharmaceuticals, and Zydus Therapeutics. Many more companies are conducting clinical trials to develop therapies for liver fibrosis and NASH.

Liver Fibrosis Market Insights:

The market size for Liver Fibrosis (NASH) in the 7MM was valued at USD 2,225 million in 2021.
The United States held the largest share of the Liver Fibrosis (NASH) Market, contributing approximately 79% of the total market size in the 7MM in 2021, when compared to other significant markets such as the EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
Among the EU5 countries, Germany boasted the highest market size for Liver Fibrosis, with USD 94 million in 2021, whereas Spain had the smallest market size for Liver Fibrosis (NASH), with USD 55 million in 2021.

The market size for Liver Fibrosis (NASH) in Japan was estimated at USD 108 Million in 2021, representing 5% of the total 7MM market.
The anticipated introduction of new therapies, including Resmetirom, Lanifibranor, Aramchol, and others, is expected to bring about changes in the total market for Liver Fibrosis (NASH) in the coming years.

Scope of the Liver Fibrosis Market Report:

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Liver Fibrosis Companies: Inventiva Pharma, Galmed Research and Development, Ltd., Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, Galectin Therapeutics Inc., Zydus Therapeutics, Axcella Therapeutics, Akero Therapeutics, Inc, Lipocine Inc., Enyo Pharma, Sagimet Biosciences Inc., 89bio Inc., HighTide Biopharma, Rivus Pharmaceuticals Inc, Novo Nordisk A/S, and others
Key Liver Fibrosis Therapies: Bevacizumab, HB0025, ST-1898 tablets, Trovax, fruquintinib+sintilimab, Cabozantinib, AMG 102, Pazopanib, tivozanib (AV-951), Belzutifan, Temsirolimus (CCI-779), CB-839, ABT-869, Nivolumab, ABT-510/Thrombospondin-1 mimetic, bevacizumab, CP-461, and others
Liver Fibrosis Therapeutic Assessment: Liver Fibrosis current marketed and Liver Fibrosis emerging therapies
Liver Fibrosis Market Dynamics: Liver Fibrosis market drivers and Liver Fibrosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Liver Fibrosis Unmet Needs, KOL’s views, Analyst’s views, Liver Fibrosis Market Access and Reimbursement

Table of Contents
1. Liver Fibrosis Market Report Introduction
2. Executive Summary for Liver Fibrosis
3. SWOT analysis of Liver Fibrosis
4. Liver Fibrosis Patient Share (%) Overview at a Glance
5. Liver Fibrosis Market Overview at a Glance
6. Liver Fibrosis Disease Background and Overview
7. Liver Fibrosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Liver Fibrosis
9. Liver Fibrosis Current Treatment and Medical Practices
10. Liver Fibrosis Unmet Needs
11. Liver Fibrosis Emerging Therapies
12. Liver Fibrosis Market Outlook
13. Country-Wise Liver Fibrosis Market Analysis (2019–2032)
14. Liver Fibrosis Market Access and Reimbursement of Therapies
15. Liver Fibrosis Market Drivers
16. Liver Fibrosis Market Barriers
17. Liver Fibrosis Appendix
18. Liver Fibrosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Liver Fibrosis Pipeline
"Liver Fibrosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Liver Fibrosis market. A detailed picture of the Liver Fibrosis pipeline landscape is provided, which includes the disease overview and Liver Fibrosis treatment guidelines.
Liver Fibrosis Epidemiology
DelveInsight's 'Liver Fibrosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Liver Fibrosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani
DelveInsight Business Research LLP
+1 469-945-7679
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.